Drug resistance as a result of B-Raf activating mutations is currently considered one of the most important clinical issues in modern melanoma therapy [39] Therefore, alternative strategies and drugs are urgently needed to overcome this challenge. The gene discussed is BRAF; the disease is melanoma.